Robert "Bob" Nelsen

Background

Robert “Bob” Nelsen is a co-founder and Managing Director of ARCH Venture Partners, one of the largest venture capital firms devoted to early-stage biotech investing ¹². He has been with ARCH since its founding as an independent firm in 1992, when he, along with Steven Lazarus, Keith Crandell, and Clinton Bybee, spun the firm out of the University of Chicago’s Argonne-Chicago Development Corporation (originally established in 1986 as a technology transfer initiative between the University of Chicago and Argonne National Laboratory) ³⁴.

Nelsen holds an MBA from the University of Chicago Booth School of Business and a BS from the University of Puget Sound with majors in Economics and Biology ¹⁵.

Over his three-decade career, Nelsen has played a significant role in the creation, early sourcing, financing, and development of more than 150 companies, with over 50 early-stage investments reaching valuations exceeding $1 billion ¹. He has had more than two dozen companies go public ⁶. Notable exits include Juno Therapeutics (acquired by Celgene for $9 billion in 2018, generating a 23x return for ARCH) ³⁷, Karuna Therapeutics (acquired by Bristol-Myers Squibb for $14 billion in 2024) ¹⁸, Array BioPharma (acquired by Pfizer for $11.4 billion in 2019) ³⁹, and GRAIL (acquired by Illumina for approximately $8 billion) ³.

Beyond investing, Nelsen is a company founder himself. He co-founded National Resilience (RESILIENCE) in 2020, a biopharmaceutical manufacturing company that raised over $800 million to address vulnerabilities in medical supply chains exposed by COVID-19 ¹⁰¹¹. He also co-founded Xaira Therapeutics in 2024, an AI drug discovery company launched with $1 billion in funding ¹². He is a co-founder of the secretive “Project Prometheus,” an AI venture alongside Amazon founder Jeff Bezos ¹³.

Nelsen has served as Trustee of the Fred Hutchinson Cancer Research Institute and the Institute for Systems Biology, and as a director of the National Venture Capital Association ¹⁵. He was named to the Forbes Midas List multiple times (ranking #16 in 2016 and appearing again in 2019 and 2025) ⁶¹⁴¹⁵ and to STAT’s 2025 STATUS List of the most influential people shaping the health industry ².

Steven Kaplan, Neubauer Family Distinguished Service Professor of Entrepreneurship and Finance at the University of Chicago Booth School of Business, has stated that Nelsen “has become one of the most prominent and successful biotech venture capitalists in the world” ¹⁰.

Stated Thesis

(Self-reported: These represent what Nelsen says publicly about his investing approach. See Inferred Thesis for analysis of actual investment behavior.)

ARCH Venture Partners describes its approach as backing “great science and great teams to build breakthrough companies” ¹⁶. Nelsen has described ARCH’s philosophy as: to “bet on great science, take risks with risk takers, tackle big problems, and to ignore convention” ²³.

Nelsen has emphasized ARCH’s independence from market sentiment and pharmaceutical industry preferences. In September 2024, he stated: “We don’t really care what the market thinks. … And we don’t really care what pharma thinks, either. We’re valuable to pharma because we think orthogonally to them” ².

On ARCH’s preference for long-term company-building over quick exits, Nelsen has said: “We want the IPO book in the seed round. We want to know who wants to build something big and stay with it” ¹⁷. He has also stated: “We don’t really care what happens in the markets as much as we are concerned about, ‘can we get a chance to get partnered early, to power these companies through cycles?’” ¹⁷.

Nelsen believes artificial intelligence and data-driven biology will enable “a more preventive, curative and equitable healthcare system” ¹⁶. In October 2024, he identified the two most important healthcare advances of the coming decade as “the understanding of the human brain, and how to increase happiness” and “the ability to make cells young again to resist and reverse disease” ¹⁸.

ARCH Managing Director Kristina Burow has described the firm as “first and foremost a company builder; we foster innovation at scale to develop new technologies and medicines as rapidly as possible” ¹⁶.

Inferred Thesis

The analysis below is based on 30 verified investments attributed to Bob Nelsen personally (from ARCH website, Crunchbase, press coverage, and board positions) ¹⁵¹⁹³.

Sector concentration (based on 30 verified investments): - Therapeutics (oncology, immunology, gene therapy, cell therapy): 15 of 30 (50%) — Juno Therapeutics, Sana Biotechnology, Lyell Immunopharma, Beam Therapeutics, Prime Medicine, Editas Medicine, Bluebird Bio, Array BioPharma, Agios Pharmaceuticals, Karuna Therapeutics, Seaport Therapeutics, Sage Therapeutics, ArsenalBio, Maze Therapeutics, Encoded Therapeutics - Genomics / diagnostics / sequencing: 5 of 30 (17%) — Illumina, GRAIL, 10x Genomics, Alnylam Pharmaceuticals, deCODE Genetics - Infectious disease / vaccines: 2 of 30 (7%) — Vir Biotechnology, Aviron - AI / computational biology: 3 of 30 (10%) — Xaira Therapeutics, Insitro, Project Prometheus - Neuroscience / neurodegeneration: 3 of 30 (10%) — Denali Therapeutics, Unity Biotechnology, Seaport Therapeutics (also counted in therapeutics) - Biomanufacturing: 1 of 30 (3%) — National Resilience - Anti-aging / longevity: 1 of 30 (3%) — Altos Labs

Note: Some companies span multiple categories. Percentages based on primary classification exceed 100% due to overlap.

Stage distribution: Nelsen and ARCH operate primarily at the earliest stages — seed and Series A — but with dramatically larger check sizes than typical seed investors. ARCH’s check sizes range from as low as $50K to $250M+ ³. Recent examples: Xaira Therapeutics launched with $1 billion (2024) ¹², Sana Biotechnology raised $700 million in its initial round (2019-2020) ²⁰, Denali Therapeutics launched with $217 million (2015) ²¹, Juno Therapeutics launched with $120 million (2013) ⁷. ARCH frequently leads or co-leads these large initial rounds.

Company-building model: A distinctive pattern is that ARCH does not merely invest — it frequently co-founds or incubates companies from scratch by pairing scientific discoveries with management teams. Of the 30 verified investments, at least 10 were co-founded or incubated by ARCH (Juno, Sana, Vir, Denali, Xaira, National Resilience, Agios, Receptos, GRAIL, Altos Labs) ^1372122.

Founder profile patterns: Nelsen consistently backs world-class scientists and repeat biotech executives, often from institutions like Genentech, Fred Hutchinson Cancer Center, Memorial Sloan Kettering, and top research universities. Sana Biotechnology was founded with former Juno Therapeutics executives ²⁰. Denali was founded by three former Genentech researchers ²¹. Xaira was co-founded with David Baker from the University of Washington Institute of Protein Design ¹².

Geographic concentration: Based on the ARCH portfolio overall, approximately 40% of portfolio companies are based in the San Francisco Bay Area, 20% in San Diego, with the remainder in Seattle, Boston, and other biotech hubs ³.

Co-investor patterns: ARCH frequently co-invests with other top-tier life sciences investors including Flagship Ventures/Pioneering, F-Prime Capital, NEA, Venrock, Third Rock Ventures, and the Alaska Permanent Fund/Crestline ^7202122. For AI-related bets, ARCH has partnered with Foresite Labs, Sequoia Capital, and Lux Capital ¹².

Notable gaps vs. stated thesis: While Nelsen talks broadly about “disruptive technologies,” his actual portfolio is overwhelmingly concentrated in life sciences and biotech. The non-biotech investments (Impinj in RFID, Stability AI, R2 Technology) are rare exceptions ¹. ARCH’s stated philosophy of “ignoring convention” is genuinely reflected in the data — the firm makes extraordinarily large bets at early stages that few other VCs would contemplate.

Fund progression (ARCH firm-level): Fund IX ($400M, 2013), Fund X ($650M, 2017), Fund XI ($1.94B, 2021), Fund XII ($2.975B, 2022), Fund XIII ($3.0B+, 2024). Total AUM approximately $12 billion ³¹⁶.

Portfolio

This table represents a subset of Nelsen’s 150+ investments. Many early-career investments (1990s-2000s) have limited publicly available records with specific dates. Where exact investment years could not be verified, founding years are used as proxies and marked with “~”.

In Their Own Words

On ARCH’s investment philosophy (September 2024): “We don’t really care what the market thinks. … And we don’t really care what pharma thinks, either. We’re valuable to pharma because we think orthogonally to them.” — Robert Nelsen, STAT News ²

On ARCH’s approach to building companies (September 2024): “We don’t really care what happens in the markets as much as we are concerned about, ‘can we get a chance to get partnered early, to power these companies through cycles?’” — Robert Nelsen, Fierce Biotech ¹⁷

On long-term company building (May 2024): “We want the IPO book in the seed round. We want to know who wants to build something big and stay with it.” — Robert Nelsen, Fierce Biotech ¹⁷

On ARCH’s contrarian approach: “Science doesn’t care what markets are doing, and science moves forward.” — Robert Nelsen, p05.org ³

On founding Denali Therapeutics (May 2015): “Denali brings together independent experts in the industry, united in our dedication to successfully tackling this critical need.” — Robert Nelsen, Denali press release ²¹

On founding National Resilience (November 2020): “We created RESILIENCE to reimagine biopharmaceutical manufacturing through unprecedented investment in technology and a best-in-class team to execute our vision. COVID-19 has exposed critical vulnerabilities in medical supply chains, and today’s manufacturing can’t keep up with scientific innovation, medical discovery, and the need to rapidly produce and distribute critically important drugs at scale.” — Robert Nelsen, RESILIENCE press release ¹¹

On the future of healthcare (October 2024): “Someone was asking me what will be the most important advances in healthcare in the coming decade. 1. The understanding of the human brain, and how to increase happiness, and 2. the ability to make cells young again to resist and reverse disease.” — Robert Nelsen, X/Twitter ¹⁸

On cell therapy breakthroughs (December 2024): “In my 40 years of biotech, I was waiting to see this result. Never before have transplanted cells survived normal immune response without immunosuppression.” — Robert Nelsen, X/Twitter ²⁹

On the COVID-19 pandemic response (March 2020): “Everyone in an enclosed space needs to have a mask.” — Robert Nelsen, STAT News ³⁰

On the biotech industry during COVID (March 2020): “Working on this is their sense of purpose like I’ve never seen, ever, with anything else.” — Robert Nelsen, STAT News ³⁰

On AI and risk (January 2025): “The development of AI and biotechnology lowers the risk. The idea that we are at more risk than at the height of the cold war, where we were actually minutes from extinction three times, shows how silly and political this has become.” — Robert Nelsen, X/Twitter ³¹

What Founders Say

No independently sourced founder testimonials found through dedicated searching. Nelsen’s portfolio founders (in biotech) tend to be recruited by ARCH rather than the other way around, which makes traditional “founder testimonials about their investor” rarer in this context. ARCH’s company-building model means Nelsen often serves as both investor and co-creator of the companies.

Steven Kaplan, Professor at the University of Chicago Booth School of Business (not a portfolio founder, but a professional colleague), has stated: “Bob has become one of the most prominent and successful biotech venture capitalists in the world” ¹⁰. This is noted for context but is not a portfolio founder testimonial.

Sources